1. Home
  2. EYPT vs BELFB Comparison

EYPT vs BELFB Comparison

Compare EYPT & BELFB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EYPT
  • BELFB
  • Stock Information
  • Founded
  • EYPT 1987
  • BELFB 1949
  • Country
  • EYPT United States
  • BELFB United States
  • Employees
  • EYPT N/A
  • BELFB N/A
  • Industry
  • EYPT Biotechnology: Laboratory Analytical Instruments
  • BELFB
  • Sector
  • EYPT Industrials
  • BELFB
  • Exchange
  • EYPT Nasdaq
  • BELFB Nasdaq
  • Market Cap
  • EYPT 741.0M
  • BELFB 865.9M
  • IPO Year
  • EYPT 2005
  • BELFB N/A
  • Fundamental
  • Price
  • EYPT $11.09
  • BELFB $131.03
  • Analyst Decision
  • EYPT Strong Buy
  • BELFB Strong Buy
  • Analyst Count
  • EYPT 7
  • BELFB 4
  • Target Price
  • EYPT $24.29
  • BELFB $113.25
  • AVG Volume (30 Days)
  • EYPT 643.4K
  • BELFB 182.8K
  • Earning Date
  • EYPT 08-06-2025
  • BELFB 07-24-2025
  • Dividend Yield
  • EYPT N/A
  • BELFB 0.21%
  • EPS Growth
  • EYPT N/A
  • BELFB N/A
  • EPS
  • EYPT N/A
  • BELFB 4.05
  • Revenue
  • EYPT $51,898,000.00
  • BELFB $594,034,000.00
  • Revenue This Year
  • EYPT N/A
  • BELFB $21.74
  • Revenue Next Year
  • EYPT N/A
  • BELFB $6.99
  • P/E Ratio
  • EYPT N/A
  • BELFB $31.75
  • Revenue Growth
  • EYPT 2.99
  • BELFB 6.08
  • 52 Week Low
  • EYPT $3.91
  • BELFB $58.00
  • 52 Week High
  • EYPT $13.99
  • BELFB $136.56
  • Technical
  • Relative Strength Index (RSI)
  • EYPT 61.85
  • BELFB 65.19
  • Support Level
  • EYPT $10.22
  • BELFB $130.07
  • Resistance Level
  • EYPT $11.28
  • BELFB $136.56
  • Average True Range (ATR)
  • EYPT 0.71
  • BELFB 4.79
  • MACD
  • EYPT 0.04
  • BELFB -0.70
  • Stochastic Oscillator
  • EYPT 89.89
  • BELFB 58.79

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

About BELFB Bel Fuse Inc. Class B

Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.

Share on Social Networks: